| Flexion Therapeutics (FLXN) | |||
|---|---|---|---|
| 9.12 0 (0%) | 12-31 19:00 | ||
| Open: | 9.14 | Pre. Close: | 9.12 |
| High: | 9.225 | Low: | 9.12 |
| Volume: | 0 | Market Cap: | 0(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 10.73 One year: 10.77 |
| Support: | Support1: 9.12 Support2: 7.59 |
| Resistance: | Resistance1: 9.18 Resistance2: 9.23 |
| Pivot: | 9.12 |
| Moving Averages: | MA(5): 9.12 MA(20): 9.12 MA(100): 8.38  MA(250): 8.53  |
| MACD: | MACD(12,26): 0.01 Signal(12,26,9): 0.01 |
| %K %D: | %K(14,3): %D(3): |
| RSI: | RSI(14): 61.02 |
| 52-Week: | High: 13.66 Low: 4.3 Change(%): -26.3 |
| Average Vol(K): | 3-Month: 600 10-Days: |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 9.252 - 9.297 | 9.297 - 9.334 |
| Low: | 8.992 - 9.055 | 9.055 - 9.106 |
| Close: | 9.033 - 9.127 | 9.127 - 9.203 |
| Price, MAs and Bollinger Bands |
|---|
| Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.FLXN has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to Flexion Therapeutics's normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - Specialty & Generic | |
| Shares Out. (M) | 50.32 |
| Shares Float (M) | 45.33 |
| % Held by Insiders | 3.09 |
| % Held by Institutions | 93.21 |
| Shares Short (K) | 1870 |
| Shares Short Prior Month (K) | 5670 |
| Stock Financials | |
|---|---|
| EPS | -1.910 |
| Book Value (p.s.) | -1.120 |
| Profit Margin | -92.52 |
| Operating Margin | -71.24 |
| Return on Assets (ttm) | -19.0 |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | 82.4 |
| Gross Profit (p.s.) | 1.322 |
| Sales Per Share | 2.042 |
| EBITDA (p.s.) | -1.415 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -59.19 |
| Levered Free Cash Flow (M) | -30.46 |
| Stock Valuation | |
|---|---|
| PE Ratio | -4.77 |
| PEG Ratio | |
| Price to Book value | -8.14 |
| Price to Sales | 4.47 |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
